TITLE:
Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis

CONDITION:
Ankylosing Spondylitis

INTERVENTION:
olsalazine

SUMMARY:

      OBJECTIVES:

      I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men
      with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and
      physiotherapy.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE: Patients are treated with daily olsalazine. The dose is increased each
      week until the protocol dose is reached.

      Supplemental acetaminophen is allowed; nonsteroidal anti-inflammatory drugs continue
      unchanged. Concurrent sulfasalazine is prohibited.
    

ELIGIBILITY:
Gender: Male
Age: 18 Years to 65 Years
Criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Meets modified New York diagnostic criteria

          -  Active disease, i.e., morning stiffness for more than 30 minutes

          -  Failed or experienced nonlife-threatening reaction to prior sulfasalazine

          -  No significant hematologic, hepatic, or renal disease
      
